Kedrion Biopharma recently participated in PPTA’s Global Plasma Summit 2020 (GPS), which for the first time in its history took place entirely in virtual mode. Kedrion has been a global member of the Plasma Protein Therapeutics Association (PPTA) since its foundation. One of the PPTA’s objectives is to increase patients’ access worldwide to plasma-derived therapies.
The GPS, which took place from the 28th to the 30th of October, brought together top experts, representatives from the industry, the world of patients, and public institutions in the interest of mutual collaboration and exchange of ideas.
During the Global Plasma Summit, Alessandro Gringeri, Chief Medical and R&D Officer of Kedrion, illustrated how the Company has reacted promptly and efficiently in the face of the health crisis caused by the Covid-19 pandemic, displaying an extraordinary capacity for interpreting this particular moment in history: through its efforts to protect the health and safety of all its employees, while also guaranteeing continuity of the company’s activities, and its commitment on the front line to developing an anti Covid-19 plasma-derived hyper immune Immunoglobulin.
On the final day of the GPS, Paolo Marcucci, President of Kedrion, was awarded the 2020 Dr. Otto Schwarz Award. It is one of the most prestigious international commendations attributed to leaders who, through their contribution to the development and growth of this sector, have distinguished themselves in the plasma-derived therapy industry. Paolo Marcucci was presented with the award for “having understood and embraced the multiple challenges that the world of industry and patient communities have to face” and “proving himself to be a global leader committed to advancing the plasma-derivatives sector in order to satisfy the demands of a population which, in the 21st century, has an increased need for lifesaving therapies produced by the members of the PPTA”.